glp-1 obesity drug news today october 23 2025 oct GLP-1 Drugs: 2025 Pulse Survey (U.S.) GLP-1 Receptor Agonists Obesity Drugs
Description
Individual response to GLP-1 medications varies
Specifically, the ELIXA (lixisenatide) trial studied patients with T2DM who had recent acute coronary syndrome and found that the addition of lixisenatide to conventional therapy did not result in a significant difference in cardiovascular endpoints relative to placebo (Table 1) [56]
doi:10.1055/s-0034-1371892 111
Future efforts should address affordability and accessibility through health economic analyses and policy-driven approaches
A review article in 2021 discussed the utility of GLP-1RA for the treatment of IIH, with a particular focus on weight management (5)
